Steven Ketchum
Chief Tech/Sci/R&D Officer at AMARIN CORPORATION PLC
Net worth: 3 M $ as of 2024-03-30
Profile
Steven B.
Ketchum is currently the Chief Scientific Officer, President-R&D, and EVP at Amarin Corp.
Plc.
He previously worked as the Senior Director of Regulatory Affairs at ALZA Corp.
from 1994 to 2002.
From 2002 to 2007, he served as the Senior VP of Operations & Regulatory Affairs at IntraBiotics Pharmaceuticals, Inc. Additionally, he held the position of Senior VP of Medical Affairs, Research & Development at Reliant Pharmaceuticals LLC from 2005 to 2008.
Dr. Ketchum was an Independent Director at Sunesis Pharmaceuticals, Inc. from 2008 to 2021.
He obtained his undergraduate degree from Stanford University and his doctorate from University College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AMARIN CORPORATION
0.65% | 2024-02-19 | 2,362,567 ( 0.65% ) | 2 M $ | 2024-03-30 |
| 2024-01-31 | 553,980 ( 0.13% ) | 493 596 $ | 2024-03-30 |
Steven Ketchum active positions
| Companies | Position | Start |
|---|---|---|
| AMARIN CORPORATION PLC | Chief Tech/Sci/R&D Officer | 2012-02-15 |
Former positions of Steven Ketchum
| Companies | Position | End |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2012-01-31 |
Reliant Pharmaceuticals LLC
 Reliant Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ | Chief Tech/Sci/R&D Officer | 2008-04-30 |
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Chief Operating Officer | 2007-01-21 |
| ALZA CORPORATION | General Counsel | 2002-04-30 |
Training of Steven Ketchum
| Stanford University | Undergraduate Degree |
| University College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AMARIN CORPORATION PLC | Health Technology |
| Private companies | 4 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Reliant Pharmaceuticals LLC
Reliant Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ | Commercial Services |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Steven Ketchum
